Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

goodrx holdings inc. - GDRX

GDRX

Close Chg Chg %
2.84 0.08 2.82%

Closed Market

2.92

+0.08 (2.82%)

Volume: 2.92M

Last Updated:

May 8, 2026, 4:00 PM EDT

Trade Now

Company Overview: goodrx holdings inc. - GDRX

GDRX Key Data

Open

$2.80

 Day Range

2.72 - 2.94

52 Week Range

1.77 - 5.81

 Market Cap

$972.91M

Shares Outstanding

342.57M

 Public Float

89.45M

Beta

1.55

 Rev. Per Employee

N/A

P/E Ratio

48.55

 EPS

$0.06

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.71M

  

GDRX Performance

1 Week
 
 14.51%
 
1 Month
 
 33.33%
 
3 Months
 
 33.94%
 
1 Year
 
 -32.41%
 
5 Years
 
 -91.59%
 

GDRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About goodrx holdings inc. - GDRX

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. It offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GDRX At a Glance

GoodRx Holdings, Inc.
2701 Olympic Boulevard
Santa Monica, California 90404
Phone 1-855-268-2822 Revenue 796.85M
Industry Medical/Nursing Services Net Income 30.44M
Sector Health Services 2025 Sales Growth 0.572%
Fiscal Year-end 12 / 2026 Employees 697
View SEC Filings

GDRX Valuation

P/E Current 48.547
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 31.77
Price to Sales Ratio 1.214
Price to Book Ratio 1.50
Price to Cash Flow Ratio 5.76
Enterprise Value to EBITDA 6.496
Enterprise Value to Sales 1.567
Total Debt to Enterprise Value 0.435

GDRX Efficiency

Revenue/Employee 1,143,261.119
Income Per Employee 43,671.449
Receivables Turnover 3.127
Total Asset Turnover 0.568

GDRX Liquidity

Current Ratio 2.614
Quick Ratio 2.614
Cash Ratio 1.064

GDRX Profitability

Gross Margin 82.089
Operating Margin 13.424
Pretax Margin 7.095
Net Margin 3.82
Return on Assets 2.171
Return on Equity 4.54
Return on Total Capital 2.626
Return on Invested Capital 2.529

GDRX Capital Structure

Total Debt to Total Equity 88.08
Total Debt to Total Capital 46.831
Total Debt to Total Assets 38.327
Long-Term Debt to Equity 86.498
Long-Term Debt to Total Capital 45.99
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Goodrx Holdings Inc. - GDRX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
766.55M 750.26M 792.32M 796.85M
Sales Growth
+2.83% -2.12% +5.61% +0.57%
Cost of Goods Sold (COGS) incl D&A
118.81M 170.09M 117.75M 142.72M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
57.53M 111.77M 69.54M 85.22M
Depreciation
7.95M 8.90M 4.50M 4.20M
Amortization of Intangibles
49.58M 102.87M 65.04M 81.02M
COGS Growth
+46.22% +43.16% -30.77% +21.20%
Gross Income
647.74M 580.17M 674.57M 654.13M
Gross Income Growth
-2.47% -10.43% +16.27% -3.03%
Gross Profit Margin
+84.50% +77.33% +85.14% +82.09%
2022 2023 2024 2025 5-year trend
SG&A Expense
610.58M 528.80M 585.28M 547.16M
Research & Development
138.88M 133.44M 123.75M 117.27M
Other SG&A
471.70M 395.36M 461.53M 429.89M
SGA Growth
-4.07% -13.39% +10.68% -6.51%
Other Operating Expense
- - - -
-
Unusual Expense
46.83M 77.03M 25.52M 19.48M
EBIT after Unusual Expense
(9.67M) (25.65M) 63.77M 87.49M
Non Operating Income/Expense
20.68M 26.81M 20.61M 11.65M
Non-Operating Interest Income
9.27M 32.17M 23.27M 10.93M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
34.24M 56.73M 52.92M 42.60M
Interest Expense Growth
+44.84% +65.66% -6.71% -19.49%
Gross Interest Expense
34.24M 56.73M 52.92M 42.60M
Interest Capitalized
- - - -
-
Pretax Income
(23.23M) (55.57M) 31.46M 56.54M
Pretax Income Growth
-128.27% -139.21% +156.61% +79.71%
Pretax Margin
-3.03% -7.41% +3.97% +7.10%
Income Tax
9.60M (46.70M) 15.07M 26.10M
Income Tax - Current - Domestic
10.09M 18.86M 26.98M 6.03M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(497.00K) (65.56M) (11.91M) 20.07M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(32.83M) (8.87M) 16.39M 30.44M
Minority Interest Expense
- - - -
-
Net Income
(32.83M) (8.87M) 16.39M 30.44M
Net Income Growth
-29.99% +72.99% +284.82% +85.72%
Net Margin Growth
-4.28% -1.18% +2.07% +3.82%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(32.83M) (8.87M) 16.39M 30.44M
Preferred Dividends
- - - -
-
Net Income Available to Common
(32.83M) (8.87M) 16.39M 30.44M
EPS (Basic)
-0.0795 -0.0216 0.0425 0.0854
EPS (Basic) Growth
-26.19% +72.83% +296.76% +100.94%
Basic Shares Outstanding
412.86M 410.31M 385.74M 356.33M
EPS (Diluted)
-0.0795 -0.0216 0.0418 0.0853
EPS (Diluted) Growth
-26.19% +72.83% +293.52% +104.07%
Diluted Shares Outstanding
412.86M 410.31M 392.17M 356.97M
EBITDA
94.69M 163.15M 158.83M 192.19M
EBITDA Growth
+44.90% +72.30% -2.65% +21.00%
EBITDA Margin
+12.35% +21.75% +20.05% +24.12%

Snapshot

Average Recommendation HOLD Average Target Price 2.885
Number of Ratings 15 Current Quarters Estimate 0.08
FY Report Date 06 / 2026 Current Year's Estimate 0.31
Last Quarter’s Earnings 0.07 Median PE on CY Estimate N/A
Year Ago Earnings 0.35 Next Fiscal Year Estimate 0.369
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 12 12 12
Mean Estimate 0.08 0.08 0.31 0.37
High Estimates 0.11 0.10 0.35 0.48
Low Estimate 0.07 0.07 0.27 0.29
Coefficient of Variance 15.85 13.13 9.72 16.23

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 4 4 5
OVERWEIGHT 1 1 1
HOLD 8 8 8
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Insider Actions for Goodrx Holdings Inc. - GDRX

Date Name Shares Transaction Value
Apr 16, 2026 Wendy Barnes See Remarks; Director 543,141 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Wendy Barnes See Remarks; Director 493,120 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.23 per share 1,099,657.60
Apr 16, 2026 Wendy Barnes See Remarks; Director 544,297 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Wendy Barnes See Remarks; Director 522,065 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.23 per share 1,164,204.95
Apr 16, 2026 Wendy Barnes See Remarks; Director 633,028 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Wendy Barnes See Remarks; Director 584,825 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.23 per share 1,304,159.75
Apr 16, 2026 Wendy Barnes See Remarks; Director 1,266,632 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Wendy Barnes See Remarks; Director 153,531 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Wendy Barnes See Remarks; Director 1,220,594 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 16, 2026 Christopher A. McGinnis See Remarks 163,308 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 16, 2026 Christopher A. McGinnis See Remarks 152,563 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.23 per share 340,215.49
Apr 16, 2026 Christopher A. McGinnis See Remarks 406,865 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 28, 2025 Douglas Joseph Hirsch Director 231,909 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Oct 28, 2025 Douglas Joseph Hirsch Director 41,042 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 10, 2025 Ian T. Clark Director 100,150 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.74 per share 474,711.00
Jul 10, 2025 Ian T. Clark Director 34,497 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Goodrx Holdings Inc. in the News